NYSE:AORT

Artivion Stock News

Healthcare > Medical - Devices

Buy AORT

*Your capital is at risk

$20.58

+0.160 (+0.784%)

At Close: Jun 03, 2026

Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Artivion, Inc. (NYSE:AORT)

02:15am, Friday, 21'st Nov 2025

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Artivion, Inc. (NYSE: AORT). In a filing disclosed on November 18th, the Representative disclosed that they had sold bet

Bridger Management LLC Purchases 68,288 Shares of Artivion, Inc. $AORT

03:50am, Tuesday, 18'th Nov 2025

Bridger Management LLC lifted its position in shares of Artivion, Inc. (NYSE: AORT) by 106.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commiss

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

05:09am, Wednesday, 12'th Nov 2025

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion

Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript

11:46pm, Thursday, 06'th Nov 2025

Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin G

Artivion (AORT) Tops Q3 Earnings and Revenue Estimates

07:16pm, Thursday, 06'th Nov 2025

Artivion (AORT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

Artivion Reports Third Quarter 2025 Financial Results

04:05pm, Thursday, 06'th Nov 2025

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP co

Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial

08:00am, Thursday, 06'th Nov 2025

ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in th

Oppenheimer Asset Management Inc. Takes Position in Artivion, Inc. $AORT

04:05am, Sunday, 02'nd Nov 2025

Oppenheimer Asset Management Inc. purchased a new stake in shares of Artivion, Inc. (NYSE: AORT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional inve

Artivion to Participate in the Stifel 2025 Healthcare Conference

04:10pm, Wednesday, 29'th Oct 2025

ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results

04:10pm, Thursday, 23'rd Oct 2025

ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial result

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

08:00am, Monday, 13'th Oct 2025

30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data fro

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by